MS and Demyelinating Disorders

Here's what is coming soon to NeurologyLive.

In assessing patients treated with siponimod, researchers also saw that plasma neurofilament light levels slightly predicted a reduced risk of disease worsening.

Students share their experience in the virtual classroom, navigating new requirements, and the lessons learned from their position in a global pandemic.

The partnership is aiming to develop a novel approach to damage repair in multiple sclerosis from a number of potential drug candidates.

Neurology News Network for the week ending March 13, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 12, 2021.

The senior investigator at the National Institutes of Neurological Disorders and Stroke discussed 2 treatments currently being evaluated for use in multiple sclerosis.

The assistant professor of neurology at Mayo Clinic detailed the areas of autoimmune encephalitis research that need more attention, as well as the diagnostic potential of autoantibody assays.

The neurologist from the University of Washington Medical Center discussed how the study of natalizumab adverse events came about and the importance of this monitoring period.

Researchers found that GCIPL thickness, along with disease duration of at least 9 years at baseline, were associated with the highest odds of EDSS worsening.

The retrospective analysis in patients aged 55 years and older underlines the importance of testing different patient populations.

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed further research she would like to see conducted with IL-1RA in MS.

The chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University discussed the takeaways from his lecture at ACTRIMS Forum 2021.

Researchers found that, in an exploratory analysis of 150 patients, African American patients with MS were most likely to become disabled and lose employment.

The chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University also offered his insight on discontinuing treatment in progressive MS.

Ishu Arpan, PhD, senior research associate at Oregon Health & Science University, discussed her team’s investigations into identifying patients with MS at risk of falling.

Here's what is coming soon to NeurologyLive.

Patients having a relapse, confirmed disability accumulation, or worsening in fatigue had significant negative impact on each of the work productivity and activity impairment measures.

The neurologist from Massachusetts General Hospital discussed physician rationales behind prescribing DMT use in RIS.

Researchers found that the percentage of telemedicine visits increased from 15% to 72.8% during the COVID-19 pandemic.

Neurology News Network for the week ending March 6, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 5, 2021.

The president of the Americas Committee for Treatment and Research in MS discusses his takeaways from this year’s virtual forum.

The assistant professor of neurology at Mayo Clinic discussed his presented talk at ACTRIMS Forum 2021 on autoimmune encephalitis.

Researchers also found that patients with progressive MS had longer disease duration before starting DMTs than those with relapsing MS.